Safety of high-dose intravitreal triamcinolone acetonide as low-cost alternative to anti-vascular endothelial growth factor agents in lower-middle-income countries

Hammouda Hamdy Ghoraba1 Department of Ophthalmology, Faculty of Medicine, Tanta University, Tanta, Egypt;2 Department of Retina, Magrabi Eye Hospital, Tanta, Egypt

Mahmoud Leila3 Retina Department, Research Institute of Ophthalmology, Giza, Egypt, [email protected]Correspondence[email protected]

Sameh Mohamed Elgouhary4 Department of Ophthalmology, Faculty of Medicine, Menoufia University, Menoufia, Egypt

Emad Eldin Mohamed Elgemai2 Department of Retina, Magrabi Eye Hospital, Tanta, Egypt;5 Department of Ophthalmology, Damanhour Teaching Hospital, Damanhour, Egypt

Haithem Mamon Abdelfattah2 Department of Retina, Magrabi Eye Hospital, Tanta, Egypt;6 Department of Ophthalmology, Banha Teaching Hospital, Banha, Egypt

Hashem Hammouda Ghoraba2 Department of Retina, Magrabi Eye Hospital, Tanta, Egypt

Mohamed Amin Heikal7 Department of Ophthalmology, Faculty of Medicine, Benha University, Benha, Egypt

show all

Citations (5)

Keep up to date with the latest research on this topic with citation updates for this article.

Safety of high-dose intravitreal triamcinolone acetonide as low-cost alternative to anti-vascular endothelial growth factor agents in lower-middle-income countries

Articles from other publishers (5)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Safety of high-dose intravitreal triamcinolone acetonide as low-cost alternative to anti-vascular endothelial growth factor agents in lower-middle-income countries

Citations (5)

Articles from other publishers (5)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date